Ms Mary Magdalene Watts, MS in Ashford, AL - Counselor

Ms Mary Magdalene Watts, MS is a Counselor - Mental Health based in Ashford, Alabama. Ms Mary Magdalene Watts is licensed to practice in * (Not Available) (license number ) and her current practice location is 1539 Sweetie Smith Rd, Ashford, Alabama. She can be reached at her office (for appointments etc.) via phone at (334) 690-8030.

NPI number for Ms Mary Magdalene Watts is 1295915882 and her current mailing address is 2694 S Park Ave, Dothan, Alabama. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1295915882.

Contact Information

	Ms Mary Magdalene Watts, MS
	1539 Sweetie Smith Rd, Ashford, AL 36312-7422
	(334) 690-8030
	(334) 691-8029

Healthcare Provider's Profile

Full Name	Ms Mary Magdalene Watts
Gender	Female
Speciality	Counselor - Mental Health
Location	1539 Sweetie Smith Rd, Ashford, Alabama
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1295915882
Provider Enumeration Date: 11/12/2007
Last Update Date: 11/12/2007

Medical Identifiers

Medical identifiers for Ms Mary Magdalene Watts such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1295915882	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
101YM0800X	Counselor - Mental Health	(* (Not Available))	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Ms Mary Magdalene Watts is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Ms Mary Magdalene Watts, MS 2694 S Park Ave, Dothan, AL 36301-4904 Ph: (334) 712-2720	Ms Mary Magdalene Watts, MS 1539 Sweetie Smith Rd, Ashford, AL 36312-7422 Ph: (334) 690-8030

News Archive

NPS announces new data from GATTEX Phase 3 study on short bowel syndrome

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced new data from STEPS 2, a long-term open-label study, showing that GATTEX (teduglutide) was associated with achieving and maintaining clinically meaningful reductions in parenteral nutrition (PN) and intravenous (IV) fluid volume in adult subjects with short bowel syndrome.

DSG's eCaseLink EDC software used in Cipher's Phase 3 dermatology study

DSG Inc., an industry leader in clinical trial data collection and management, today announced that Cipher Pharmaceuticals (TSX:DND) is using electronic data capture (EDC) software and data management services from DSG. Cipher is using DSG's eCaseLink™ for its Phase 3 dermatology study on its new compound for the treatment of severe acne.

Will Obamacare website be able to transfer Medicaid enrollment data?

Politico raises questions about whether the transfer of Medicaid enrollment data to 36 states participating in the federal exchange will go smoothly Nov. 1 when it's slated to begin. The Los Angeles Times looks at how Ohio Gov. John Kasich's decision to pursue Medicaid expansion in defiance of the right wing of his party may affect his political future.

New step in the proofreading process that helps maintain accuracy of DNA replication identified

Wayne State researchers have for the first time observed the movement of a single molecule of DNA polymerase as it incorporates nucleotides one by one. More significantly, they have identified a previously unknown step that they speculate is part of the proofreading process known to prevent the polymerase from producing cancer-causing mutations.

FDA approves Astepro nasal spray 0.15% for the treatment of the symptoms of seasonal allergies

The U.S. Food and Drug Administration (FDA) has approved Astepro (azelastine) nasal spray 0.15% for the treatment of the symptoms of seasonal and perennial allergic rhinitis.

Ms Mary Magdalene Watts, MS - Counselor in Ashford, AL